Zokinvy (lonafarnib) — Highmark
Hutchinson-Gilford Progeria Syndrome (HGPS, Progeria)
Initial criteria
- age ≥ 12 months
- diagnosis of HGPS (Progeria)
- documentation of mutation in LMNA gene
- body surface area (BSA) ≥ 0.39 m2
- requested dosing regimen aligns with FDA-approved labeled dosing regimen (refer to Table 1)
Reauthorization criteria
- age ≥ 12 months
- diagnosis of HGPS (Progeria)
- documentation of mutation in LMNA gene
- body surface area (BSA) ≥ 0.39 m2
- requested dosing regimen aligns with FDA-approved labeled dosing regimen (refer to Table 2)
Approval duration
initial up to 4 months; maintenance up to 12 months